Therefore, tumors harboring acquired T790M mutation, acquired EGFR amplification, and EGFR‐sensitive mutations may synergistically amplify the reliance of tumor cells on the EGFR pathway at a molecular level. This evidence concerns the gene EGFR and neoplasm.